{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:15:12Z","timestamp":1758593712803,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"820","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Soins"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.soin.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T20:16:54Z","timestamp":1510863414000},"page":"22-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Les nouveaux traitements de l\u2019insuffisance cardiaque"],"prefix":"10.1016","volume":"62","author":[{"given":"Cl\u00e9ment","family":"Venner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Huttin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Selton-Suty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Juilli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soin.2017.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soin.2017.09.004_bib0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soin.2017.09.004_bib0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soin.2017.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ejhf.343","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials: Characteristics of included RCTs NOACs in patients with concomitant AF and HF","volume":"17","author":"Xiong","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.soin.2017.09.004_bib0025","first-page":"891","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.soin.2017.09.004_bib0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2008.07323.x","article-title":"Virchow and his triad: a question of attribution","volume":"143","author":"Bagot","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.soin.2017.09.004_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The warfarin\/aspirin study in heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.soin.2017.09.004_bib0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study","volume":"8","author":"Cokkinos","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.soin.2017.09.004_bib0045","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soin.2017.09.004_bib0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ejhf.266","volume":"17","author":"Zannad","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10.1016\/j.soin.2017.09.004_bib0055","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soin.2017.09.004_bib0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soin.2017.09.004_bib0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.soin.2017.09.004_bib0070","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Soins"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0038081417303079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0038081417303079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:48:14Z","timestamp":1758527294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0038081417303079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":14,"journal-issue":{"issue":"820","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0038081417303079"],"URL":"https:\/\/doi.org\/10.1016\/j.soin.2017.09.004","relation":{},"ISSN":["0038-0814"],"issn-type":[{"type":"print","value":"0038-0814"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les nouveaux traitements de l\u2019insuffisance cardiaque","name":"articletitle","label":"Article Title"},{"value":"Soins","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soin.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}